[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338372-105":59,"doc-detail-338372-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","stat3-key-targets-of-growth-promoting-receptor-positive-breast-cancer","STAT3: Key targets of growth-promoting receptor positive breast cancer","","Breast cancer is the most common malignant tumor among women and ranks high in mortality. Most cases fall into luminal-type or HER2-positive categories, driven by distinct genes that drive proliferation, metastasis, and treatment failure. STAT3 is a critical breast cancer-associated gene; clinical and basic studies show that overexpression and constitutive activation support tumor progression and chemotherapy resistance. Targeting STAT3 with small-molecule inhibitors offers a potential therapeutic strategy for luminal and HER2-positive subtypes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stat3-key-targets-of-growth-promoting-receptor-positive-breast-cancer/338372/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stat3-key-targets-of-growth-promoting-receptor-positive-breast-cancer/338372.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is STAT3 considered important in growth-promoting receptor positive breast cancer?","Question",{"text":113,"@type":114},"Clinical and basic research indicates that overexpressed and constitutively activated STAT3 contributes to breast cancer progression, proliferation, metastasis, and chemotherapy resistance. It is described as a key target affecting treatment outcomes in luminal-type and HER2-positive cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is breast cancer classified in the article?",{"text":118,"@type":114},"The article describes three molecular types based on ER, PR, and HER2 expression: luminal (ER- or PR-positive), HER2-positive, and triple-negative breast cancer (ER-/PR-/HER2-). Luminal type B is also categorized as HER2-positive or HER2-negative depending on HER2 expression.",{"name":120,"@type":111,"acceptedAnswer":121},"What treatment approach targeting STAT3 is discussed?",{"text":122,"@type":114},"The article states that small-molecule inhibitors targeting STAT3 can effectively treat breast cancer and improve the efficacy of treatment methods for luminal-type and HER2-positive subtypes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338372,1790823087,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Jiang et al. Cancer Cell International (2024) 24:356 [https://doi.org/10.1186/s12935-024-03541-9](https://doi.org/10.1186/s12935-024-03541-9)  \nCancer Cell International  \n REVIEW Open Access  \nSTAT3: Key targets of growth-promoting receptor positive breast cancer  \nRui-yuan Jiang1,2†, Jia-yu Zhu 1,2†, Huan-ping Zhang2,3†, Yuan Yu2, Zhi-xin Dong4, Huan-huan Zhou1,2* and Xiaojia Wang2*  \nAbstract  \nBreast cancer has become the malignant tumor with the first incidence and the second mortality among female cancers. Most female breast cancers belong to luminal-type breast cancer and HER2-positive breast cancer. These breast cancer cells all have different driving genes, which constantly promote the proliferation and metastasis of breast cancer cells. Signal transducer and activator of transcription 3 (STAT3) is an important breast cancer-related gene, which can promote the progress of breast cancer. It has been proved in clinical and basic research that overexpressed and constitutively activated STAT3 is involved in the progress, proliferation, metastasis and chemotherapy resistance of breast cancer. STAT3 is an important key target in luminal-type breast cancer and HER2-positive cancer, which has an important impact on the curative effect of related treatments. In breast cancer, the activation of STAT3 will change the spatial position of STAT3 protein and cause different phenotypic changes of breast cancer cells. In the current basic research and clinical research, small molecule inhibitors activated by targeting STAT3 can effectively treat breast cancer, and enhance the efficacy level of related treatment methods for luminal-type and HER2-positive breast cancers.  \nKeywords STAT3, Breast cancer, Oncogene, Growth-promoting, Cell growth, Small molecule inhibitors  \n†Rui-yuan Jiang, Jia-yu Zhu and Huan-ping Zhang are co-first authors.  \n*Correspondence: Huan-huan Zhou [zhhuan77@163.com](zhhuan77@163.com)[ ](zhhuan77@163.com)Xiaojia Wang [wxiaojia0803@163.com](wxiaojia0803@163.com)  \n1 The Second School of Clinical Medicine, Zhejiang Chinese Medical University, NO. 548, Binwen Road, Binjiang District, Hangzhou 310000, Zhejiang, China  \n2 Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China  \n3 Department of Graduate Student, Wenzhou Medical University, No. 270, Xueyuan West Road, Lucheng District, Wenzhou 325027, Zhejiang, China  \n4 Department of Oncology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9, Dongge Road, Qingxiu District, Nanning 530000, Guangxi, China  \nIntroduction  \nBreast cancer (BRCA) incidence and mortality rates are rapidly rising worldwide, making it the most common malignant tumor in women since 2021, accounting for over 30% of all newly diagnosed cancers [1]. According to the American Cancer Society, approximately 281,500 new breast cancer cases were recorded in the United States in 2021, with an estimated 43,600 deaths. According to the prediction model, it was estimated that 287,850 new cases of breast cancer and approximately 4,3250 deaths occurred in the United States in 2022 [2]. In most developing and developed countries, cancer is among the leading causes of \"premature death\" among residents [3]. The term \"premature death\" refers to the death of adults aged between 30 and 70. Breast cancer is classified into three molecular types based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 receptor (HER2)  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not h","cbCaigp6p8e7qkIS","https://ap.wps.com/l/cbCaigp6p8e7qkIS","pdf",2389353,41,"English","# Introduction\n## Breast cancer classification and epidemiology\n# Background\n## Luminal, HER2-positive, and triple-negative subtypes\n## Growth-promoting receptor-positive concept\n# Therapeutic target rationale\n## STAT3 as a key gene and signaling node\n## STAT3 activation effects and treatment resistance\n# Therapeutic implications\n## Small-molecule STAT3 inhibitors for luminal and HER2-positive breast cancer","[{\"question\":\"Why is STAT3 considered important in growth-promoting receptor positive breast cancer?\",\"answer\":\"Clinical and basic research indicates that overexpressed and constitutively activated STAT3 contributes to breast cancer progression, proliferation, metastasis, and chemotherapy resistance. It is described as a key target affecting treatment outcomes in luminal-type and HER2-positive cancers.\"},{\"question\":\"How is breast cancer classified in the article?\",\"answer\":\"The article describes three molecular types based on ER, PR, and HER2 expression: luminal (ER- or PR-positive), HER2-positive, and triple-negative breast cancer (ER-/PR-/HER2-). Luminal type B is also categorized as HER2-positive or HER2-negative depending on HER2 expression.\"},{\"question\":\"What treatment approach targeting STAT3 is discussed?\",\"answer\":\"The article states that small-molecule inhibitors targeting STAT3 can effectively treat breast cancer and improve the efficacy of treatment methods for luminal-type and HER2-positive subtypes.\"}]","STAT3: Key targets of growth-promoting receptor positive breast cancer | PDF",1790023308,103]